Current Therapy in Amyotrophic lateral sclerosis (ALS): a review on Past and Future Therapeutic Strategies
Y Wei, S Zhong, H Yang, X Wang, B Lv, Y Bian… - European Journal of …, 2024 - Elsevier
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that affects the first
and second motoneurons (MNs), associated with muscle weakness, paralysis and finally …
and second motoneurons (MNs), associated with muscle weakness, paralysis and finally …
Therapeutic neuroprotective agents for amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is a fatal chronic neurodegenerative disease whose
hallmark is proteinaceous, ubiquitinated, cytoplasmic inclusions in motor neurons and …
hallmark is proteinaceous, ubiquitinated, cytoplasmic inclusions in motor neurons and …
Potential therapeutic drugs and methods for the treatment of amyotrophic lateral sclerosis
G Yacila, Y Sari - Current medicinal chemistry, 2014 - ingentaconnect.com
Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder caused by damage of
motoneurons leading to paralysis state and long term disability. Riluzole is currently the only …
motoneurons leading to paralysis state and long term disability. Riluzole is currently the only …
Emerging drugs for the treatment of amyotrophic lateral sclerosis: a focus on recent phase 2 trials
A Barp, F Gerardi, A Lizio, VA Sansone… - Expert Opinion on …, 2020 - Taylor & Francis
Introduction Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative
disease involving both upper and lower motor neurons and resulting in increasing disability …
disease involving both upper and lower motor neurons and resulting in increasing disability …
[HTML][HTML] New developments and opportunities in drugs being trialed for amyotrophic lateral sclerosis from 2020 to 2022
JS Jiang, Y Wang, M Deng - Frontiers in pharmacology, 2022 - frontiersin.org
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder that
primarily affects motor neurons in the brain and spinal cord. In the recent past, there have …
primarily affects motor neurons in the brain and spinal cord. In the recent past, there have …
Pharmacotherapy for amyotrophic lateral sclerosis: a review of approved and upcoming agents
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disorder
involving loss of upper and lower motor neurons, with most cases ending in death within 3–5 …
involving loss of upper and lower motor neurons, with most cases ending in death within 3–5 …
Current and prospective disease-modifying therapies for amyotrophic lateral sclerosis
JA Morren, N Galvez-Jimenez - Expert Opinion on Investigational …, 2012 - Taylor & Francis
Introduction: Amyotrophic lateral sclerosis (ALS) is a devastating illness of unclear etiology
affecting motor neurons. It causes unremitting muscle paralysis, atrophy and death usually …
affecting motor neurons. It causes unremitting muscle paralysis, atrophy and death usually …
Emerging drug targets in amyotrophic lateral sclerosis
MP Bova, GG Kinney - Expert Opinion on Orphan Drugs, 2013 - Taylor & Francis
Introduction: Amyotrophic lateral sclerosis (ALS) is a progressive and devastating
neurodegenerative disease resulting from injury and death of upper and lower motor …
neurodegenerative disease resulting from injury and death of upper and lower motor …
[HTML][HTML] Amyotrophic lateral sclerosis: drug therapy from the bench to the bedside
SB Gibson, MB Bromberg - Seminars in neurology, 2012 - thieme-connect.com
Amyotrophic lateral sclerosis (ALS) is an unrelenting progressive neurodegenerative
disease causing progressive weakness, ultimately leading to death. Despite aggressive …
disease causing progressive weakness, ultimately leading to death. Despite aggressive …
Diagnosis, pathogenesis and therapeutic targets in amyotrophic lateral sclerosis
J Costa, C Gomes… - CNS & Neurological …, 2010 - ingentaconnect.com
Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease of the motor
system. The diagnosis is clinical, but additional investigations such as electromyography …
system. The diagnosis is clinical, but additional investigations such as electromyography …